Unstimulated Peripheral Blood Mononuclear Cells from Patients with the Hyper-IgD Syndrome Produce Cytokines Capable of Potent Induction of C-Reactive Protein and Serum Amyloid A in Hep3B Cells

Joost P. H. Drenth,† Jos W. M. Van Der Meer,‡ and Irving Kushner*  
The hyper-IgD and periodic fever syndrome (HIDS) and familial Mediterranean fever (FMF) are both characterized by attacks of periodic fever accompanied by acute phase responses that are substantially higher in HIDS than in FMF. To determine whether this difference could be due to differences in production of acute phase protein-inducing mediators, we studied PBMC from HIDS and FMF patients in the inactive phase of disease. Unstimulated PBMC from patients with inactive HIDS released significantly more IL-1β, IL-6, and TNF-α than did PBMC from patients with FMF, but unstimulated PBMC from the latter group released significantly more IL-1β and IL-6 compared with controls. Conditioned medium (CM) derived from PBMC of patients with inactive HIDS induced significantly greater CRP production and significantly higher mRNAs for CRP and SAA in Hep3B cells than did CM derived from the PBMC of patients with inactive FMF. Stimulation of PBMC with LPS led to further increases in cytokine production and in acute phase protein-inducing ability in both patient groups and in controls. These findings suggest that the greater acute phase response seen in HIDS compared with FMF reflects greater production of acute phase protein-inducing cytokines in the former patients and indicates that PBMC from inactive HIDS patients are already activated in vivo. Finally, the finding of both quantitative and qualitative differences in cytokine production by unstimulated PBMC from HIDS and FMF patients supports the likelihood of different pathogeneses of these diseases.  

*Department of Medicine, MetroHealth Medical Center, Cleveland, OH 44109; and †Department of Medicine, Division of General Internal Medicine, University Hospital St. Radboud, Nijmegen, The Netherlands  
Received for publication January 11, 1996. Accepted for publication April 15, 1996.  
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.  
1 J.P.H.D. is a recipient of a Dutch Organization for Scientific Research fellowship for Clinical Investigators (KWO 900–716–065) and of an NWO travel grant. This work was supported by National Institutes of Health Grant AG-02467.  
2 Address correspondence and reprint requests to Dr. Jos W. M. Van Der Meer, Department of Medicine, Division of General Internal Medicine, University Hospital St. Radboud, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.  
3 Abbreviations used in this paper: HIDS, hyper-IgD periodic fever syndrome; FMF, familial Mediterranean fever; CM, conditioned medium; CRP, C-reactive protein; SAA, serum amyloid A; AGP, α1-acid glycoprotein; FMF-CM, conditioned medium prepared from peripheral blood mononuclear cells derived from patients with familial Mediterranean fever; C-CM, conditioned medium prepared from peripheral blood mononuclear cells derived from control adults; HIDS-CM, conditioned medium prepared from peripheral blood mononuclear cells derived from patients with hyper-IgD syndrome; TBS, Tris-buffered saline; OPD, o-phenylenediamine.  

Inflammatory states are often accompanied by increased plasma concentrations of a group of acute phase proteins, including C-reactive protein (CRP), serum amyloid A (SAA), fibrinogen, and α1-acid glycoprotein (AGP) (4). A number of inflammation-associated cytokines, particularly IL-1, IL-6, and TNF-α are considered the main inducers of their synthesis (5). Febrile attacks in both HIDS and FMF are accompanied by an acute phase response, which, however, differs in intensity. In HIDS, substantially higher serum concentrations of acute phase proteins are achieved during attacks than are seen in FMF (6–8). This variation in acute phase response between the two syndromes could theoretically be due to a different quality of a hypothetrical inflammatory stimulus, to differences in production of inflammatory mediators influencing plasma protein synthesis, or to different responses of hepatocytes.  

PBMC produce a wide range of cytokines capable of acute phase protein induction after exposure to bacterial LPS (9), and conditioned medium (CM) from such LPS-stimulated PBMC has been shown to induce acute phase reactants in human hepatoma cell lines (10, 11). Accordingly, we explored possible differences between these two periodic fever syndromes in production of acute phase protein-inducing mediators by comparing the abilities of PBMC from HIDS and FMF patients to produce three inflammation-associated cytokines. In addition, we compared the abilities of their CM both to induce production of the protein CRP and to induce expression of the mRNAs for the two major human acute phase protein genes, CRP and SAA, in the human hepatoma cell line Hep3B.  

Materials and Methods  
Patients  
Eight patients with HIDS (four male, mean age: 25.9 yr); six patients with FMF (three male, mean age: 25.3 yr); and seven healthy Dutch volunteers (seven males, mean age: 30.3 yr) took part in the study. The diagnoses of HIDS and FMF were made according to standard criteria listed elsewhere.
Peripheral blood was drawn into sterile 10-ml tubes containing 0.2 mg EDTA. PBMC were isolated by buoyant density gradient centrifugation on Ficoll (12). The cells from the interphase were aspirated and washed twice with sterile saline. After the last washing, cells were resuspended at a concentration of 5 X 10^6/ml in RPMI 1640 medium (Dutch modification; Flow Labs, Irvine, Scotland) supplemented with 2 mM l-glutamine, 1 mM pyruvate, and 500 µg/ml gentamicin. Medium was loaded onto a 50-ml syringe and forced through a 0.2-µm filter by manual force to remove endotoxin and other cytokine-inducing material (13). Heat-inactivated (30 min at 50°C) pooled human sera (5%) was added after filtration. PBMC were resuspended at a concentration of 5 X 10^6/ml in round-bottom 96-well plastic tissue culture plates and incubated either with or without 100 ng/ml pokeweed mitogen (PWM) to stimulate the PBMC and 10 ml of 10% CM. The medium was collected after 24 h and stored at -70°C until assay.

**Cultures of Hep3B cells**

Human hepatoma cells, Hep3B, were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cells were subcultured weekly using trypsinization. Induction of acute phase proteins was conducted when the cells were confluent, usually on day 6 after subculture. Hep3B cells were incubated at 37°C in 35-mm dishes containing a total of 0.5 ml RPMI 1640 supplemented with 1 µM dexamethasone and 10% CM. The medium was collected after 24 h and stored at -70°C until assay.

**ELISAs**

CRP and SAA concentrations were measured in duplicate in sera obtained from patients and healthy controls at the time of isolation of the PBMC and from media of Hep3B cells by ELISAs as previously reported (14, 15). Immuno III Divadistrp wells were coated overnight at 4°C with 1:100 dilution of goat anti-human CRP, IgG fraction (Atlantic Antibodies no. 89134) in 100 µl Tris-buffered saline (TBS). After three washes with 200 µl PBS containing 1% Tween-20, 200 µl of 1% BSA in TBS was added to each well to block nonspecific binding. Samples were diluted in glass tubes in RPMI 1640 with 1% BSA. Wells were washed before 100-µl aliquots of samples and standards were added and incubated at 37°C for 2 h. After three washes, 100 µl of PBS containing 1 ng/ml biotinylated sheep anti-human CRP (Cappel Laboratories, West Chester, PA; no. 55522) was added. This Ab was biotinylated using Pierce (Rockford, IL) Immunopure NHS-LC Biotin according to the manufacturer’s protocol. After washing, 100 µl of a 1:1000 dilution of goat anti-biotin peroxidase conjugate (diluted 1:1000 in PBS) was added and incubated for 1 h at 37°C. Wells were washed before the substrate was added (OPD kit; Sigma Chemical Co., St. Louis, MO). The reaction was stopped by 2 M H₂SO₄ and absorbance was measured at 490 nm.

**Statistical analysis**

All results are shown as the mean ± SEM. Comparison between groups was assessed by the unpaired nonparametric Mann Whitney U test. A p value of <0.05 was considered to be the lowest level of significance.

**Results**

**Serum concentrations of acute phase proteins**

The CRP content in serum drawn from the patients was higher compared with the healthy control group, albeit the difference was not statistically significant (Table I). Serum from HIDS patients and FMF patients contained comparable quantities of SAA but the concentrations were (marginally significantly) higher compared with the control group.

**Cytokine production by PBMC**

The concentrations of cytokines in CM, reflecting production by PBMC over 24 h of incubation, are indicated in Table II. CM derived from unstimulated PBMC from HIDS patients (HIDS-CM) contained significantly more IL-1β, IL-6, and TNF-α than
Table 1. CRP and SAA content of serum from HIDS and FMF patients and from healthy controls as measured by specific ELISA assays.

<table>
<thead>
<tr>
<th></th>
<th>HIDS</th>
<th>FMF</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mg/L)</td>
<td>4.1 ± 1.8</td>
<td>5.9 ± 2.5</td>
<td>0.17 ± 0.03</td>
</tr>
<tr>
<td>SAA (mg/L)</td>
<td>6.9 ± 5.7</td>
<td>14.3 ± 7.9</td>
<td>0.27 ± 0.05</td>
</tr>
</tbody>
</table>

*Data are expressed as mean ± SEM in ng/ml.

Discussion

The major purpose of the current investigation was to determine the extent to which clinically observed differences in the magnitude of the acute phase response in HIDS and FMF patients, as measured by serum levels of acute phase proteins, could be attributed to differences in release of inflammatory cytokines by PBMC from these patients (Refs. 6–8; and J. P. H. Drenth, personal observations). We found that unstimulated PBMC from patients with inactive HIDS released significantly more IL-1β and IL-6, and TNF-α than did PBMC from patients with FMF, and that CM from these cells induced significantly greater CRP production and significantly more mRNA for CRP and SAA in Hep3B cells than did CM from FMF patients. These results support the hypothesis that differences in the magnitude of the acute phase response between HIDS and FMF patients reflect differences in cytokine production by their PBMC and indicate that these effects on acute phase protein production are exerted at the pretranslational level. We studied PBMC rather than monocytes because isolation of monocytes involves an adherence step that may itself activate these cells, which we wanted to avoid. To the extent to which findings in PBMC reflect the behavior of monocytes and tissue macrophages, our findings raise the possibility that macrophages may also produce large amounts of these inflammatory cytokines in patients with HIDS. The results from our study cannot be explained by differences in monocyte content in the PBMC since this was similar for all studied groups.

Serum SAA and CRP concentrations (determined during disease inactivity) were relatively low in both patient groups, although greater than those seen in controls, and did not correlate with acute phase protein-inducing activity of the samples we tested. This came as no surprise, since in vivo and in vitro circumstances are quite different. Our in vitro assay is relatively insensitive, based on protracted exposure of Hepatoma cells to an unchanging test sample, while in vivo acute phase protein levels reflect effects of continuous flow of plasma on in situ hepatocytes and of clearance of acute phase proteins from plasma.

In addition, our findings also indicate that PBMC are already markedly activated in vivo in patients with inactive HIDS. In contrast, unstimulated PBMC from patients with inactive FMF produced substantially less IL-1β and IL-6, and their TNF-α production was indistinguishable from that seen in PBMC from healthy controls. Overproduction of cytokines by unstimulated PBMC from HIDS patients could be due either to faulty regulation of autonomous cytokine production or to the effects of an exogenous stimulatory factor. Recent findings favor the latter explanation; IgD isolated from HIDS patients has been found to stimulate normal human PBMC to produce large quantities of IL-1β, IL-6, TNF-α, and leukocyte inhibitory factor. (19). It is reasonable to conclude, in light of our current findings, that the high concentrations of IgD seen in these patients serve as a continuous stimulus to inflammatory cytokine production, even during clinically inactive periods. This conclusion is consistent with our previous observation that increased fucosylation of AGP, a phenomenon shown to be due to the effects of cytokines (20), is found in HIDS patients during asymptomatic intervals. The finding that CM derived from unstimulated PBMC from HIDS patients in the intercritical phase is able to induce an acute phase response in Hep3B cells, a relatively insensitive bioassay (21), supports this conclusion, as does the observation that serum AGP concentrations are persistently elevated between attacks and increase slightly during febrile attacks of HIDS (20).

There has been similar interest in the effect of CM derived from circulating cells on the synthesis of acute phase proteins in other inflammatory disorders. Patients with active Crohn’s disease generally have higher circulating CRP concentrations compared with those with ulcerative colitis (22). IL-1β and TNF-α production by unstimulated peripheral monocytes was not different in cells from patients with Crohn’s disease than in those with ulcerative colitis, but LPS-stimulated cytokine production was significantly higher in monocytes from Crohn’s disease patients (22) and this difference was even greater during active disease. CM from both unstimulated and stimulated monocytes from patients with active Crohn’s disease induced greater release of CRP from PLC/PRF/5 human hepatoma cells than did CM from patients with active ulcerative colitis (23). Similarly, CM from unstimulated and LPS-stimulated
The authors thank Dr. G. Lozanski, Department of Medicine, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, for his efforts to develop an accurate ELISA for CRP measurement and for continuous support throughout these studies; and Debra Rzewnicki for help in preparation of this manuscript. H. Roelofs, Laboratory of Gastrointestinal

FIGURE 1. Effect of CM (10%) from unstimulated PBMC of patients with HIDS (■), FMF (□), and healthy controls (■) (C-CM) on the production of CRP from Hep3B cells. Supernatants were harvested after 24 h of incubation and CRP concentrations determined. Results are expressed as mean ± SEM. HIDS-CM caused significantly more CRP production than did FMF-CM and C-CM (**, p < 0.01).

FIGURE 2. Effect of CM from unstimulated PBMC (upper panel) and LPS-stimulated PBMC (lower panel) of patients with HIDS (■), FMF (□), and healthy controls (■) on production of CRP from Hep3B cells. Supernatants were harvested after 24 h of incubation and CRP concentrations determined. Results are expressed as fold increase over unstimulated Hep3B cells. *, p < 0.05 for HIDS patients compared with FMF patients.

FIGURE 3. Effect of CM from LPS-stimulated PBMC of HIDS (■), FMF (□), and healthy controls (■) on production of CRP from Hep3B cells. Hep3B cells were incubated with 10% CM obtained from PBMC stimulated with 100 ng/ml E. coli LPS. After 24 h, supernatants were harvested and CRP concentrations determined. Results are expressed as mean ± SEM. Stimulated HIDS-CM caused significantly more CRP production than did FMF-CM and C-CM (**, p < 0.01).

PBMC from patients with rheumatoid arthritis significantly increased production of α1-antichymotrypsin and α1-proteinase inhibitor by HepG2 cells over levels achieved by CM from PBMC of patients with active systemic lupus erythematosus (24). The differences we observed in the profile of cytokines produced by unstimulated PBMC from patients with inactive HIDS and FMF indicate both qualitative and quantitative differences in cytokine production in patients with these two periodic inflammatory disorders during intercritical periods. Unstimulated PBMC from FMF patients produced significantly more IL-6 and IL-1β, but not TNF-α, than did PBMC from normal controls, while PBMC from HIDS patients produced significantly more of all three cytokines than did FMF PBMC. Taken together with the observation that supernatants from both unstimulated and LPS-stimulated PBMC from HIDS and FMF patients differed in their capacity to elicit CRP production and acute phase protein mRNA changes in Hep3B cells, these findings suggest differences in the pathogenesis of these two intermittent febrile disorders.

Finally, the observation that HIDS PBMC, although already activated, were able to respond to LPS stimulation with further increase in cytokine production and increased acute phase protein-inducing capability is consistent with the hypothesis that acute febrile attacks are precipitated by unknown stimuli capable of further increasing cytokine production. There is evidence that the ability to produce cytokines in HIDS patients increases during febrile attacks. In these patients, LPS-stimulated ex vivo production of TNF-α and IL-1β, as measured in a whole blood culture system, was found to be significantly greater during acute attacks than following defervescence (6). In contrast, LPS-stimulated TNF-α and IL-1β production in supernatants of PBMC from FMF patients was markedly decreased during febrile attacks but normalized during recovery (25–27). This apparent differential regulation of cytokines during attacks in these two syndromes might further explain the difference in the magnitude of the acute phase response observed in vivo.

Acknowledgments

The authors thank Dr. G. Lozanski, Department of Medicine, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, for his efforts to develop an accurate ELISA for CRP measurement and for continuous support throughout these studies; and Debra Rzewnicki for help in preparation of this manuscript. H. Roelofs, Laboratory of Gastrointestinal

### Table II. IL-1β, IL-6, and TNF-α content of CM from PBMC of HIDS and FMF patients from healthy controls as measured by specific ELISA assays

<table>
<thead>
<tr>
<th></th>
<th>HIDS</th>
<th>FMF</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β</td>
<td>3.2 ± 1.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.64 ± 0.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.048 ± 0.4</td>
</tr>
<tr>
<td>IL-6</td>
<td>11.7 ± 4.6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5.1 ± 2.8&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.068 ± 0.017</td>
</tr>
<tr>
<td>TNF-α</td>
<td>1.5 ± 0.75&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.072 ± 0.04</td>
<td>0.065 ± 0.012</td>
</tr>
<tr>
<td>LPS-Stimulated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIDS</td>
<td>63 ± 7.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>19.8 ± 3.3</td>
<td>22 ± 6.9</td>
</tr>
<tr>
<td>FMF</td>
<td>150 ± 20.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>73 ± 4.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>15.3 ± 8</td>
</tr>
<tr>
<td>Controls</td>
<td>7.4 ± 2.4</td>
<td>5.5 ± 2.9</td>
<td>1.4 ± 0.8</td>
</tr>
</tbody>
</table>

<sup>a</sup>CM was prepared from unstimulated PBMC or from PBMC stimulated with 100 ng/ml LPS. Data are expressed as mean ± SEM in ng/ml.

<sup>b</sup>Indicates difference (p < 0.05) compared to FMF.

<sup>c</sup>Indicates difference (p < 0.05) compared to controls.
and Liver Diseases, University Hospital St. Radboud, Nijmegen, The Netherlands, is acknowledged for the superb technical support in earlier phases of the study. Dr. A. Livneh, Tel Hashomer, Israel, is thanked for his cooperation in pursuing the study.

References


